- Home
- MCRB vs CNTX Comparison
MCRB vs CNTX Comparison
Compare MCRB & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | CNTX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 47.7M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCRB | CNTX |
|---|---|---|
| Price | $2.12 | $0.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $17.00 | $4.03 |
| AVG Volume (30 Days) | 70.9K | ★ 979.0K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $789,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $0.22 |
| 52 Week High | $29.98 | $3.62 |
Technical Indicators
Market Signals| Indicator | MCRB | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 19.80 | 27.97 |
| Support Level | N/A | N/A |
| Resistance Level | $9.53 | $0.36 |
| Average True Range (ATR) | 0.21 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 13.73 | 14.35 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.